Catheter Precision, Inc. (VTAK) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Catheter Precision, Inc. is a medical technology company focused on cardiac electrophysiology (EP) following a 2023 merger with "Old Catheter." The company discontinued its legacy DABRA laser business to focus on the VIVO System (3D cardiac mapping) and LockeT (suture retention device). The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Revenue | $96,000 | $133,000 | $271,000 | $314,000 |
| Net Loss | $(4,120,000) | $(1,927,000) | $(11,015,000) | $(69,903,000) |
| Operating Loss | $(2,859,000) | $(2,730,000) | $(8,192,000) | $(75,522,000) |
| Cash & Equivalents (End of Period) | $1,268,000 | $5,579,000 | $1,268,000 | $5,579,000 |
| Accumulated Deficit | $(286,724,000) | $(275,040,000) | $(286,724,000) | $(275,040,000) |
| Notes Payable (Related Party) | $1,500,000 | $0 | $1,500,000 | $0 |
| Royalties Payable (Liability) | $9,797,000 | $6,974,000 | $9,797,000 | $6,974,000 |
Note: All figures in thousands except per share data. YTD 9M 2023 includes a $60.9 million non-cash goodwill impairment charge.
Material Changes vs. Prior Period
- Revenue Decline: Q3 revenue decreased 28% year-over-year to $96,000, primarily due to lower VIVO System sales from a key hospital that placed a large order in late 2023. This was partially offset by the first commercial sales of the LockeT device ($62,000 in Q3).
- Operating Expenses: SG&A expenses increased slightly in Q3 ($2.88M vs $2.75M) due to hiring a new Chief Commercial Officer and expanding the sales force, offset by lower professional fees. YTD SG&A decreased significantly ($8.25M vs $14.39M) due to the absence of one-time merger-related legal and accounting fees incurred in 2023.
- Non-Cash Charges: The YTD 2023 net loss was heavily impacted by a $60.9 million goodwill impairment charge. In Q3 2024, the company recorded a $1.23 million non-cash expense related to the change in fair value of royalties payable.
- Capital Structure: The company completed a 1-for-10 reverse stock split in July 2024. In September 2024, it raised approximately $2.6 million in net proceeds from a public offering. Additionally, it secured $1.5 million in related-party promissory notes.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for 12 months from the filing date. Cash on hand ($1.3M at quarter-end, estimated $4.4M as of Nov 1, 2024) is insufficient to fund operations through late 2025 or repay debt due in January 2026 without additional financing.
- Financing Needs: The company is actively evaluating debt or equity transactions and bridge loans. Failure to secure funding may require suspending operations or seeking creditor relief.
- Subsequent Events: In October 2024, the company executed a Warrant Inducement Offer, raising an estimated $3.7 million gross proceeds by repricing existing warrants to $0.70/share. This transaction is expected to provide additional liquidity.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, including lack of segregation of duties and errors in royalty accounting. A remediation plan is underway.
- Product Outlook: LockeT CE Mark approval is expected in March 2025. The company is expanding its sales force to drive VIVO and LockeT adoption.
Investor Verification Checklist
- Liquidity Runway: Verify the actual cash balance as of the filing date and the status of the October 2024 Warrant Inducement Offer proceeds.
- Debt Maturity: Confirm the repayment plan for the $1.5 million related-party notes due January 31, 2026, which carry a 12% interest rate.
- Royalty Liability: Review the assumptions used to value the $9.8 million royalty payable liability, as changes in discount rates or sales projections significantly impact net income.
- Revenue Concentration: Assess the risk associated with the top three customers representing 90% of Q3 revenue.
- Internal Controls: Monitor progress on the remediation of material weaknesses in financial reporting to ensure future filing reliability.